ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00050999
Recruitment Status : Completed
First Posted : January 3, 2003
Last Update Posted : March 5, 2008
Sponsor:
Information provided by:
Eisai Inc.

Brief Summary:
The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma, T-Cell, Cutaneous Mycosis Fungoides Sezary Syndrome Drug: ONTAK Phase 4

Study Type : Interventional  (Clinical Trial)
Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25
Study Start Date : June 1995
Actual Primary Completion Date : September 2006
Actual Study Completion Date : December 2006





Primary Outcome Measures :
  1. Objective Rate of Response (ORR), defined as CR + CCR + PR

Secondary Outcome Measures :
  1. Time-to-Treatment Failure
  2. Time-to-Progression
  3. Duration of Response


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histopathologically confirmed recurrent or persistent CTCL as determined by reference pathology lab;
  • Patient must have had 1 to 3 prior CTCL therapies. Repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. Only 1 prior combination cytotoxic regimen is permitted. Topical or systemic steroids are not considered a therapy;
  • Interleukin-2 receptor (IL-2R) expression on at least 20% of tumor cells as determined by immunohistochemistry.
  • Stage IA - III disease and unlikely to progress during the first month on study. Life expectancy of at least 12 months.
  • Measurable or evaluable disease. Lymph node involvement no greater than LN2. No CTCL involvement of bone marrow.
  • No active CNS disease, kidney or liver disease, significant pulmonary disease, or cardiac disease.
  • No systemic infections;
  • Willingness to be randomized to a placebo treatment only arm;
  • ECOG performance status 0 or 1;

Exclusion Criteria:

• Patients must not have previously received treatment with DAB389IL-2 or DAB486IL 2 (previous candidate compound evaluated in a clinical setting).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00050999


  Show 35 Study Locations
Sponsors and Collaborators
Eisai Inc.
Investigators
Study Director: Elyane Lombardy, M.D. Ligand Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00050999     History of Changes
Obsolete Identifiers: NCT00002683
Other Study ID Numbers: 93-04-11
First Posted: January 3, 2003    Key Record Dates
Last Update Posted: March 5, 2008
Last Verified: February 2008

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Mycoses
Mycosis Fungoides
Sezary Syndrome
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Denileukin diftitox
Antineoplastic Agents